Skip to content
Adrienne Monson – Lifestyle
Author:
Cue Biopharma, Inc.
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
April 30, 2026
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
April 30, 2026
Cue Biopharma Announces 1-for-30 Reverse Stock Split
April 22, 2026
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
April 15, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
April 8, 2026
←
Previous Page
1
2